Compare Moderna, Inc. (MRNA) vs Ryanair Holdings plc (RYAAY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Ryanair Holdings plc — how do they compare? Moderna, Inc. trades at $137.39 (market cap $56.02B), while Ryanair Holdings plc trades at $54.25 (market cap $27.58B). The key difference: Moderna, Inc. is far larger — about 2× Ryanair Holdings plc's market cap, and Ryanair Holdings plc pays a 1.65% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals.
| MRNA | RYAAY | |
|---|---|---|
Market Cap | $56.02B | $27.58B |
Sector | Health | Industrials |
52-Week High | $174.38 | $73.82 |
52-Week Low | $22.36 | $53.24 |
Enterprise Value | $52.17B | $24.53B |
Dividend Yield | — | 1.65% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $140.33, down 3.59% on the day, but maintains a bullish technical signal with support at $138 and resistance at $145. Recent positive phase 3 cancer vaccine trial results have driven significant stock appreciation, though financials show declining revenue and negative net income margins. The company has beaten EPS estimates for the last three quarters, with Q3 2026 results pending.
The outlook is mixed; promising clinical developments in oncology offer long-term growth potential, but high valuation multiples and persistent losses pose risks. Analyst consensus is cautious with a $90.08 price target below the current price, reflecting concerns over profitability and competitive pressures in the mRNA therapeutics space.
RYAAY trades at $54.37, down 1.79% on the day, with a bearish technical signal from moving averages. The company reported mixed Q2 2026 earnings, missing EPS estimates but showing strong revenue growth trends. Recent news highlights operational challenges including traffic outlook reductions and cost pressures from unhedged fuel. Cash flow remains positive from operations but net cash flow turned negative in 2025 and 2026 projections.
The outlook is cautious due to near-term headwinds from fuel costs and competitive pricing, but long-term fundamentals remain solid with attractive valuation multiples. Investment opportunity exists for value-oriented investors given low P/E of 13.09 and strong profitability metrics. Key risks include oil price volatility and winter capacity constraints affecting profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Ryanair Holdings plc
Ryanair is the leading airline group by passenger numbers in Europe. The company employs a low-cost no-frills model to offer low fares to leisure customers on short-haul intra-European routes. In 2020, the most recent pre-pandemic fiscal year, the company carried 149 million passengers, utilizing a fleet of 467 Boeing 737 aircraft across its 1,800 routes. To keep costs low the company serves predominantly lower-cost secondary airports. The company generated sales of EUR 8.5 billion in fiscal 2020.
Read more on RYAAY →
